ARS Pharmaceuticals (SPRY) Total Non-Current Liabilities (2021 - 2026)

ARS Pharmaceuticals has disclosed Total Non-Current Liabilities across 5 years of filings, most recently posting $221.8 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $221.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $221.8 million (changed N/A YoY), and the FY2025 annual result was $208.8 million, up 121.28% from the prior year.
• Total Non-Current Liabilities came in at $221.8 million for Q1 2026 at ARS Pharmaceuticals, up from $208.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $221.8 million in Q1 2026 to a low of $8.5 million in Q4 2022.
• The 4-year median for Total Non-Current Liabilities is $164.3 million (2025), against an average of $145.8 million.
• Across the five-year window, Total Non-Current Liabilities slumped 48.48% in 2022 and surged 121.28% in 2025, its largest moves.
• ARS Pharmaceuticals' Total Non-Current Liabilities stood at $8.5 million in 2022, then surged by 1003.7% to $94.4 million in 2024, then surged by 121.28% to $208.8 million in 2025, then increased by 6.22% to $221.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $221.8 million (Q1 2026), $208.8 million (Q4 2025), and $221.4 million (Q3 2025), per Business Quant data.